SABS

SAB Biotherapeutics, Inc. SABS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-22.49M

Quarter to Jun 30

Free cash flow

$-11.43M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$266.76M total
Caligan Partners LP
$31.07M0.0%
Vivo Capital, LLC
$28.47M-36.1%
PERCEPTIVE ADVISORS LLC
$25.85M+3.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$24.98M+88.1%
RA CAPITAL MANAGEMENT, L.P.
$17.17M0.0%
BALYASNY ASSET MANAGEMENT L.P.
$14.67M0.0%
BlackRock, Inc.
$11.96M+917.5%
VANGUARD CAPITAL MANAGEMENT LLC
$11.59M+19.2%
Commodore Capital LP
$11.19M-34.8%
MILLENNIUM MANAGEMENT LLC
$10.72M-9.4%
Spruce Street Capital LP
$8.57M0.0%
Sessa Capital IM, L.P.
$8.57M0.0%
Affinity Asset Advisors, LLC
$5.95M+165.2%
BOOTHBAY FUND MANAGEMENT, LLC
$5.78M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$4.98M+322.9%
Woodline Partners LP
$4.60M-58.6%
Ensign Peak Advisors, Inc
$4.57M-14.8%
Propel Bio Management, LLC
$4.20M+6.3%
Soleus Capital Management, L.P.
$3.51M-14.3%
Seven Fleet Capital Management LP
$2.87M+636.1%
AMERIPRISE FINANCIAL INC
$2.38M-58.6%
STATE STREET CORP
$2.07M+615.1%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.71MNew
DV EQUITIES, LLC
$1.56M--
AWM Investment Company, Inc.
$1.46M-6.2%
See all 93 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SABS

Earnings Per Share

13fpro.ai/company/SABS

Loading ratio trend…

SABS key financials by period

Reported revenue, net income and operating margin by fiscal year, from SAB Biotherapeutics, Inc.'s annual filings on SEC EDGAR.

SAB Biotherapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$1.3M$-34.1M—
FY 2023$2.2M$-42.2M—
FY 2022$23.9M$-18.7M-121.0%
FY 2021$60.9M$-17.1M-22.0%
FY 2020$55.2M$20.1M37.2%
Source: SABS filings on SEC EDGAR →

SABS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About SAB Biotherapeutics, Inc. (SABS): stock profile, AI score and financials

SAB Biotherapeutics, Inc. (SABS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SABS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), SAB Biotherapeutics, Inc. reports net income of $-22.5M, free cash flow of $-11.4M. Top institutional holders of SABS by reported 13-F value include Caligan Partners, Vivo Capital, PERCEPTIVE ADVISORS, based on the most recent SEC filings. SABS trades on the Nasdaq exchange and files with the SEC under CIK 1833214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SABS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SAB Biotherapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1833214 →